Back to top

Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential

Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potential

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ACADIA Pharmaceuticals Inc. (ACAD)

Taysha Gene Therapies, Inc. (TSHA)